1 week Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,200 shares of the company’s stock, valued at approximately $50,000.
Several other hedge funds also recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its position in ORIC Pharmaceuticals by 22.
9% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after buying an additional 2,520 shares in the last quarter.
China Universal Asset Management Co. Ltd. grew its stake in ORIC Pharmaceuticals by 10.
3% in the fourth quarter. China Universal Asset Management Co. Ltd.
now owns 14,963 shares of the company’s stock valued at $121,000 after acquiring an additional 1,395 shares during the period. AlphaQuest LLC increased its holdings in shares of ORIC Pharmaceuticals by 2,597.8% during the fourth quarter.
AlphaQuest LLC now owns 28,435 shares of the company’s stock valued at $229,000 after acquiring an additional 27,381 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of ORIC Pharmaceuticals by 3.
8% during the third quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company’s stock worth $361,000 after purchasing an additional 1,279 shares during the period.
Finally, Verition Fund Management LLC raised its position in shares of ORIC Pharmaceuticals by 25.6% during the third quarter. Verition Fund Management LLC now owns 42,980 shares of the company’s stock worth $441,000 after purchasing an additional 8,752 shares during the period.
Institutional investors own 95.05% of the company’s stock. ORIC Pharmaceuticals Trading Up 14.
2 %Shares of ORIC Pharmaceuticals stock opened at $4.92 on Friday. The firm has a market capitalization of $349.
45 million, a P/E ratio of -2.70 and a beta of 1.38.
The business’s fifty day simple moving average is $7.40 and its 200 day simple moving average is $8.67.
ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.
67. ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($0.
51) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01.
Analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.
Analyst Ratings ChangesSeveral analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st.
JPMorgan Chase & Co. boosted their price objective on ORIC Pharmaceuticals from $21.00 to $22.
00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. Wedbush reissued an “outperform” rating and issued a $20.
00 price target on shares of ORIC Pharmaceuticals in a research report on Thursday, March 20th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, January 14th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.
com, the stock has a consensus rating of “Buy” and an average target price of $18.86.Read Our Latest Stock Analysis on ORIC PharmaceuticalsAbout ORIC Pharmaceuticals (Free Report)ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States.
Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.Featured StoriesFive stocks we like better than ORIC PharmaceuticalsEarnings Per Share Calculator: How to Calculate EPSJPMorgan is a Buy, if You Can Handle The Volatility Insider Buying Explained: What Investors Need to KnowUnited States Steel’s Crash: An Unmissable Buying OpportunityBiggest Stock Losers – Today’s Biggest Percentage DeclinersRocket Lab Stock: Weathering the Storm, Time for a Comeback?.
